NCT06556563Phase 3Active not recruiting

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

Study sponsor: NovoCure GmbH

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2029-04Estimated
Enrollment · participants741Estimated
Source updated2026-11-06Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview